Kidney Transplant Rejection Market Report 2026

The kidney transplant rejection market size has grown strongly in recent years. It will grow from $3.51 billion in 2025 to $3.76 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to increasing kidney transplant procedures, advancements in histopathological assessment techniques, wider availability of immunosuppressive drugs, growth of transplant center networks, improving post-transplant patient survival rates.

The kidney transplant rejection market size is expected to see strong growth in the next few years. It will grow to $5.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to rising demand for personalized immunosuppression strategies, increasing adoption of molecular diagnostics, expansion of precision medicine in transplant care, growing focus on long-term graft survival, increasing investment in transplant monitoring technologies. Major trends in the forecast period include increasing adoption of biomarker-based rejection monitoring, rising use of genomics-based diagnostic approaches, growing optimization of immunosuppressive therapy protocols, expansion of non-invasive rejection surveillance methods, enhanced focus on early detection of chronic rejection.

The increasing occurrence of end‑stage renal disease is anticipated to drive the expansion of the kidney transplant rejection market in the coming years. End‑stage renal disease (ESRD) denotes the ultimate, irreversible phase of chronic kidney disease in which the kidneys cannot perform adequately without dialysis or a kidney transplant. The prevalence of end‑stage renal disease is growing due to the rising rates of chronic conditions, diabetes, and hypertension, which progressively impair kidney function and result in kidney failure. Kidney transplant rejection necessitates advanced monitoring and therapeutic strategies, directly aiding the management of end‑stage renal disease by ensuring that transplanted kidneys continue to function and patients maintain kidney health. For example, in September 2024, according to the National Institute of Diabetes and Digestive and Kidney Diseases, a US-based government institute, more than 808,000 individuals in the United States were living with end-stage kidney disease (ESKD), also referred to as end-stage renal disease (ESRD), in 2023, with 68% receiving dialysis and 32% having undergone a kidney transplant. Consequently, the growing prevalence of end-stage renal disease is fueling the growth of the kidney transplant rejection market.

Leading companies operating in the kidney transplant rejection market are focusing on developing innovative diagnostic solutions, such as noninvasive urinary biomarker testing, to enable faster, safer, and more accurate detection of transplant rejection. Noninvasive urinary biomarker testing analyzes urine samples to detect molecular indicators of kidney inflammation or rejection, helping clinicians identify transplant complications quickly and safely without the need for invasive biopsies. For example, in May 2024, Thermo Fisher Scientific Inc., a US-based biotechnology company, launched the CXCL10 testing service, an innovative diagnostic tool for kidney transplant recipients. The CXCL10 test detects the CXCL10 chemokine in urine, which is associated with early transplant rejection and inflammation. It delivers results within 24 hours, enabling quicker clinical decisions, reducing the need for unnecessary biopsies, and improving patient convenience by utilizing noninvasive sample collection. Developed and validated by Thermo Fisher’s One Lambda Laboratories, the assay combines high sensitivity and specificity with ease of use in clinical settings, supporting better post-transplant care and patient outcomes.

In July 2024, Biogen Inc., a US-based biotechnology company, acquired Human Immunology Biosciences for an undisclosed amount. With this acquisition, Biogen aimed to strengthen and expand its immunology and rare-disease pipeline by incorporating late-stage therapeutic assets and expertise in immune-mediated diseases. Human Immunology Biosciences is a US-based clinical-stage biotechnology company specializing in kidney transplant rejection.

Major companies operating in the kidney transplant rejection market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., ChugAI Pharmaceutical Co. Ltd., Eurofins Scientific SE, Illumina Inc., Natera Inc., CareDx Inc., Azurity Pharmaceuticals Inc., Insight Molecular Diagnostics, and RenalytixAI plc.

Tariffs are impacting the kidney transplant rejection market by increasing costs of imported diagnostic reagents, genomic testing kits, laboratory equipment, and specialized biologic therapeutics used in rejection detection and management. Transplant centers and diagnostic laboratories in North America and Europe are most affected due to reliance on cross-border supply chains for advanced testing technologies, while Asia-Pacific faces rising costs for imported immunological assays. These tariffs are contributing to higher diagnostic and treatment expenses and slowing adoption of advanced monitoring tools. However, they are also encouraging local manufacturing of diagnostic consumables, regional laboratory capability development, and increased investment in domestically produced transplant care solutions.

The kidney transplant rejection market research report is one of a series of new reports that provides kidney transplant rejection market statistics, including kidney transplant rejection industry global market size, regional shares, competitors with a kidney transplant rejection market share, detailed kidney transplant rejection market segments, market trends and opportunities, and any further data you may need to thrive in the kidney transplant rejection industry. This kidney transplant rejection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Kidney transplant rejection is an immune-mediated condition in which the recipient’s immune system identifies the transplanted kidney as foreign and mounts a response against it, resulting in impaired graft function or graft failure. It can occur as hyperacute, acute, or chronic rejection, each with distinct immunological mechanisms and clinical features. Management of kidney transplant rejection focuses on early detection, prevention, and treatment to preserve graft function and improve patient outcomes.

The principal types of kidney transplant rejection include chronic and acute rejection. Chronic rejection involves the gradual loss of kidney function over time due to immune-mediated damage to the transplanted organ. Treatments typically include immunosuppressive drugs and therapies targeting antibody-mediated rejection. Diagnostic approaches involve biomarker-based and genomics-based methods. Therapeutic options include small molecule inhibitors and biologic therapies, and the end users include transplant centers, hospitals, diagnostic laboratories, and pharmacies.

The kidney transplant rejection market includes revenues earned by entities through transplant monitoring and diagnostic testing, immunological and histopathological assessments, clinical management of rejection episodes, immunosuppressive therapy administration and optimization, patient follow-up, and post-transplant care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.